Reviewing Competitive Technologies (OTCMKTS:CTTC) & Nuwellis (NASDAQ:NUWE)
by Sarita Garza · The Markets DailyNuwellis (NASDAQ:NUWE – Get Free Report) and Competitive Technologies (OTCMKTS:CTTC – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.
Institutional and Insider Ownership
3.1% of Nuwellis shares are held by institutional investors. 1.6% of Nuwellis shares are held by company insiders. Comparatively, 17.5% of Competitive Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Nuwellis and Competitive Technologies”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nuwellis | $8.27 million | 1.07 | -$17.52 million | ($64.02) | -0.05 |
| Competitive Technologies | N/A | N/A | N/A | N/A | N/A |
Competitive Technologies has lower revenue, but higher earnings than Nuwellis.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Nuwellis and Competitive Technologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nuwellis | 1 | 0 | 0 | 0 | 1.00 |
| Competitive Technologies | 0 | 0 | 0 | 0 | 0.00 |
Given Competitive Technologies’ higher probable upside, analysts clearly believe Competitive Technologies is more favorable than Nuwellis.
Profitability
This table compares Nuwellis and Competitive Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nuwellis | -214.90% | -32,351.83% | -249.08% |
| Competitive Technologies | N/A | N/A | N/A |
Summary
Competitive Technologies beats Nuwellis on 5 of the 8 factors compared between the two stocks.
About Nuwellis
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
About Competitive Technologies
Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.